Joint project
MAD-CoV 2 - Modern approaches for developing antivirals against SARS-CoV 2
Funder: European Union
Period: 2020-2024
URI: https://cordis.europa.eu/project/id/101005026
Abstract:
Coordinated multi-disciplinary effort to develop therapy against coronavirus outbreaks
Response to the SARS-CoV-2 pandemic and future coronavirus outbreaks requires an organised effort and the rapid translation of scientific findings to industry partners. The EU-funded MAD-CoV 2 project has assembled a multi-disciplinary team of researchers and innovative industry partners to study the virus infections in host cells and rapidly translate knowledge into new medicines and public health measures. Angiotensin-converting enzyme 2 (ACE2) is a promising drug target for treating cardiovascular diseases and also serves as the cell entry point for some coronaviruses. The objectives of MAD-CoV 2 are to uncover the role of ACE2 in viral replication and COVID-19 pathogenesis and translate this knowledge into novel therapies to fight coronavirus outbreaks. Moreover, the project will develop new strategies for developing antivirals against SARS-CoV2 and other emerging viral diseases.
Coordinated multi-disciplinary effort to develop therapy against coronavirus outbreaks
Response to the SARS-CoV-2 pandemic and future coronavirus outbreaks requires an organised effort and the rapid translation of scientific findings to industry partners. The EU-funded MAD-CoV 2 project has assembled a multi-disciplinary team of researchers and innovative industry partners to study the virus infections in host cells and rapidly translate knowledge into new medicines and public health measures. Angiotensin-converting enzyme 2 (ACE2) is a promising drug target for treating cardiovascular diseases and also serves as the cell entry point for some coronaviruses. The objectives of MAD-CoV 2 are to uncover the role of ACE2 in viral replication and COVID-19 pathogenesis and translate this knowledge into novel therapies to fight coronavirus outbreaks. Moreover, the project will develop new strategies for developing antivirals against SARS-CoV2 and other emerging viral diseases.
Cooperation partners with funding
- Medical University of Vienna
- National Veterinary Institute
